NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01137032,Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population,https://clinicaltrials.gov/study/NCT01137032,,COMPLETED,The purpose of this study is to determine the effect of PandelÂ® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.,YES,Psoriasis|Atopic Dermatitis,DRUG: Pandel Cream 0.1%,"Post-injection Serum Cortisol Level, The number of subjects with a post-injection serum cortisol level less than or equal to 18 ug/dL on Day 22., 22 Days","Pre-injection Serum Cortisol Levels, The number of subjects with pre-injection serum cortisol levels less than or equal to 5 ug/dL Day 22., 22 Days|and the Number of Subjects With an Increment Between Basal and 30 Minutes Day 22 of at Least 7 ug/dL., 22 days",,Fougera Pharmaceuticals Inc.,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,19,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,ALT 0153-01-1,2004-06,2005-08,2005-08,2010-06-04,2016-02-26,2016-05-04,"Christopher Huerter, MD, Omaha, Nebraska, 68130, United States|Oswald Mikell, MD, Hilton Head Island, South Carolina, 29926, United States|Michael Gold, MD, Nashville, Tennessee, 37215, United States",
